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Abstract During acute myocardial infarction (AMI),
ischemia leads to necrotic areas surrounded by border
zones of reversibly damaged cardiomyocytes, showing
membrane flip-flop. During reperfusion type IIA secretory
phopholipase A2 (sPLA2-IIA) induces direct cell-toxicity
and facilitates binding of other inflammatory mediators on
these cardiomyocytes. Therefore, we hypothesized that the
specific sPLA2-IIA-inhibitor PX-18 would reduce cardio-
myocyte death and infarct size in vivo. Wistar rats were
treated with PX-18 starting minutes after reperfusion, and
at day 1 and 2 post AMI. After 28 days hearts were ana-
lyzed. Furthermore, the effect of PX-18 on membrane flip-
flop and apoptosis was investigated in vitro. PX-18 sig-
nificantly inhibited sPLA2-IIA activity and reduced infarct
size (reduction 73 ± 9%, P \ 0.05), compared to the
vehicle-treated group, without impairing wound healing.
In vitro, PX-18 significantly reduced reversible membrane
flip-flop and apoptosis in cardiomyocytes. However, no
sPLA2-IIA activity could be detected, suggesting that
PX-18 also exerted a protective effect independent of
sPLA2-IIA. In conclusion, PX-18 is a potent therapeutic
to reduce infarct size by inhibiting sPLA2-IIA, and possi-
bly also by inhibiting apoptosis of cardiomyocytes in a
sPLA2-IIA independent manner.
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Introduction
Current acute myocardial infarction (AMI) treatment
focuses on reperfusion of the ischemic myocardium. This
reperfusion, however, results in the induction of inflam-
mation in the heart, which has been shown to inflict
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additional damage to the myocardium, hence termed
ischemia/reperfusion (I/R)-injury [1–3]. We have previ-
ously shown that ischemia not only results in areas of
irreversibly damaged cardiomyocytes, but also in border
zones of morphologically normal, reversibly damaged
cardiomyocytes surrounding these necrotic areas [4]. It can
be speculated that inflammation targets these reversibly
damaged cardiomyocytes in the border zones of infarction,
presumably subsequent to alterations in the plasma
membrane.
Namely, after AMI, damaged cardiomyocytes lose their
membrane phospholipid asymmetry [5]. As a result, the
anionic phospholipids phosphatidylserine and phosphati-
dylethanolamine, which under normal conditions are kept
within the inner plasma membrane leaflet, are exposed in
the outer membrane leaflet, a process called flip-flop [6].
We and others have shown that this flip-flop can be
reversible [7, 8]. However, during reperfusion the inflam-
matory mediator type IIA secretory-type phospholipase A2
(sPLA2-IIA) was shown to bind to and to induce death in
these flip-flopped cardiomyocytes [4, 8, 9].
sPLA2-IIA is a 14 kDa acute-phase protein that cataly-
ses the hydrolysis of cellular phospholipids to liberate non-
esterified fatty acids [10]. The concomitant formation of
lysophospholipids facilitates binding of C-reactive protein
(CRP) [11]. This binding of CRP then induces binding and
activation of complement, resulting in further tissue dam-
age [12]. In addition sPLA2-IIA can not only induce cell
death via CRP and complement activation, but also via a
direct cytotoxic effect, independent of other inflammatory
mediators [8].
We hypothesized that inhibition of sPLA2-IIA by the
specific inhibitor PX-18 [13] might reduce cardiomyocyte
death and infarct size in vivo. We further hypothesized that
inhibition of sPLA2-IIA would not impair wound healing
after AMI, since sPLA2-IIA inhibition would protect the
reversibly damaged cardiomyocytes, while the irreversibly
damaged cardiomyocytes would still be cleared from the
myocardium independent of sPLA2-IIA [8]. In this study,
we therefore analyzed the effect of PX-18 on membrane
flip-flop (reversibly damaged and/or apoptotic cells), both
in vitro and in vivo in a rat AMI model.
Materials and methods
Rat AMI
This study was approved by the VU animal ethics and wel-
fare committee. Female Wistar rats (Harlan Laboratories,
Horst, The Netherlands, 240–280 g) were anaesthetized
using 3% isoflurane (for initiation, maximal 10 min) and
subcutaneous hypnorm/dormicum (fentanyl ? fluanisone
0.5 ml/kg, midazolam 5 mg/kg) injection. Rats were venti-
lated (70 breaths/min, 10–0.5 mbar, Zoovent ventilator, The
Netherlands), and heart rate was monitored using Einthoven
I ECG.
A left thoracothomy was performed between the fourth
and fifth rib, after which a 6.0 ethilon suture was placed
around the left anterior descending coronary artery. For the
ligation we used a special device that allowed us to pull the
suture in one simple movement, reducing the chance of
preconditioning, but also minimalizing the chance of
damage to the occluded artery (since the suture can not cut
into the artery). As rats used in the present study were
healthy non atherosclerotic rats, no obstruction in the
coronary artery was present subsequent to the removal of
the ligation, facilitating successful reperfusion.
Ischemia was maintained for 40 min, followed by
reperfusion. AMIrats were blindly divided into 2 groups,
the treatment group (n = 17) received the sPLA2-IIA
inhibitor PX-18 (kindly provided by RBA Pharma, LLC,
Bethesda, Maryland, USA in a formulation by Supratek
Pharma Inc, Quebec, Canada), the control group (n = 13)
received vehicle (NaCl 0.9%). Treatment was given in
three daily intravenous doses in the tail vein, (10 mg/kg
each) starting directly after reperfusion. 28 days after AMI
heart function was analyzed with 2D-echocardiography,
using a 13 MHz linear-array transducer (ProSound SSD-
4000 PureHD, Aloka, Tokyo, Japan), and rats were
sacrificed.
Blood was obtained from rats 5 days after AMI. Also
sham operated controls were included in this study (n = 4).
Histological staining
Hearts were cut into five equal slices (Fig. 1a), fixed in 4%
formaldehyde and embedded in paraffin. Then a phospho-
tungstic acid haematoxylin (PTAH)-histological staining
was performed on 4 lm sections. For this slides were
incubated in Bouin-solution (73% v/v saturated picrinic
acid solution, 25% v/v formaldehyde (37%), 2% v/v glacial
acetic acid) at 60C for 30 min, followed by an incubation
in PTAH-solution (0.1% v/v hematoxilin, 1% v/v phos-
photungstic acid in distilled water) at 60C for 60 min.
Infarct size, total left-ventricle area and wall-thickness
were quantified in the lower 3 slides (Fig. 1a) using
Q-PRODIT analysis (Leica micro-systems, Cambridge,
UK). Slides cut from above the ligature were not analyzed,
since no infarcted tissue was found in this area of the heart.
In sham operated rats, it was found that suture placement
itself caused granulation tissue formation and fibrosis in the
suture area of maximal 0.01% of the total left ventricle
area. Therefore, in other groups rats with an infarct size
\0.01%, were excluded from further analysis (in total two
vehicle treated rats).
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Immunohistochemistry
To analyze inflammatory cells and the putative depositions
of sPLA2-IIA in the heart, we performed immunohisto-
chemical stainings., using a rabbit-anti-human MPO anti-
body (1:500 dilution, DakoCytomation, Eindhoven, The
Netherlands), a mouse-anti-rat-CD68 antibody (1:100
dilution, MCA341R Serotec, Kidlington, UK), a mouse-
anti-rat ED2 antibody (dilution 1:200, a kind gift from Prof
C.D. Dijkstra, Amsterdam, the Netherlands)[14], and a
rabbit-anti-human/rat-sPLA2-IIA antibody (1:100 dilution,
ab23705, ABCAM, Cambridge, UK). Antigen retrieval
was performed using 0.1% pepsin for CD68 and sPLA2-IIA
(in 0.02 M HCl, 300, 37C), or by heat activation in Citrate
(pH 6) for MPO and ED2. Primary antibodies were incu-
bated for 60 min. For secondary antibody anti-rabbit and
anti-mouse EnVision-HRP (DakoCytomation) was used.
Staining was visualized using EnVision-diaminobenzidine
(DakoCytomation). Control sections were incubated with
PBS instead of the primary antibody, and yielded no
staining at all (not shown). Numbers of extravascular
positive cells were quantified in the entire left ventricle of
the cross sections, distinguishing between viable and
infarcted areas.
Cell culture
Neonatal rat cardiomyoblasts (H9c2 cells; ATCC, Manas-
sas, Virginia, USA) were cultured in Dulbecco’s Modified
Eagles Medium (DMEM; BioWhittaker, Verviers, Bel-
gium) containing 10% Fetal Calf Serum (BioWhittaker),
100 IU/ml penicillin, 100 lg/ml streptomycin and 2 mM
L-Glutamin (all from Gibco, Paisly, England), in a
humidified atmosphere of 5% CO2 at 37C. Simvastatin
(25 lM, simvastatin-lactone, a gift from Merck & Co., Inc,
Rahway NJ, USA), mevalonate (250 lM, Sigma, St. Louis,
MO, USA), zVAD-fmk (a pan-caspase inhibitor, 25 lM,
zVAD; Alexis Biochemicals, San Diego, CA, USA) and
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Fig. 1 PX-18 reduces infarct size in a rat model of AMI. a Schematic
overview of rat heart. Hearts were cut into five pieces. Slides were cut
from the upper surface of each piece. Only the lower three slides were
used for infarct area quantification, since no infarct was found in the
slides cut from the area above the ligature. b Infarct size compared to
the vehicle group was decreased with 73 ± 9% in rats receiving
PX-18 (P \ 0.05, one-sided t-test), based on PTAH staining.PTAH
staining of the anterior wall of sham operated (c) and vehicle-treated
(d, e) rats. Vital myocardium is stained blue, fibrosis red (see arrows).
c Epicardial scar tissue and granulation tissue due to suture placement
is visible in sham-operated rat heart (see arrow). d, e Infarcted
myocardium (arrows) contains sites of fibrosis (*) and infiltration of
inflammatory cells (#). Magnification C,D:12x, E:200x
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PX-18 (0.2 mg/ml) were all added to the cultures 24 h
before harvesting. Simvastatin has been shown to induce a
significant amount of membrane flip-flop and apoptosis in
cardiomyocytes [15]. We therefore used simvastatin to
induce (reversible) plasma membrane flip-flop and apop-
tosis in this study. Simvastatin was activated by dilution (to
1 mM concentration) in 0.1 mol/l NaOH for 30 min prior
to incubation. Simvastatin was activated using NaOH,
since commercial statins are offered as a lactone form. The
activation step by NaOH converts the simvastatin into the
more active acid form. As a stock solution, PX-18 was
dissolved in PBS containing 10 mM NaOH, pH = 7.4. The
final concentration used of PX-18 (0.2 mg/ml) in vitro was
comparable to the concentration in blood in vivo.
Membrane flip-flop analysis
Flip-flop in H9c2 cells was analyzed using flow cytometry.
For this, cells were collected and stained with annexin
V-FITC (1:40 dilution, Bender Med Systems, Vienna,
Austria) for 30 min at 37C in serum-free medium. Pro-
pidium iodide was added immediately prior to measure-
ment (PI, 1:40 dilution, Bender Med Systems) and was
used to assess membrane permeability, and thus cell death.
Cells were analyzed using a FACSCalibur flow cytometer
(Becton Dickinson, Franklin Lakes, NJ, USA).
Active caspase 3 concentration measurements
Caspase 3 activity in H9c2 cells was determined using
a fluorimetric homogeneous caspase assay (Roche,
Mannheim, Germany), according to the manufacturer’s
instructions. In brief, cells were lysed and incubated with
DEVD-rhodamine 110 substrate for 1 h at 37C. Subse-
quently, the amount of free rhodamine was determined in a
microplate fluorescence reader (TECAN spectrafluor,
Hombrektikon, Switzerland).
sPLA2-IIA activity measurements
sPLA2-IIA activity was measured in the lysates and culture
medium of cells subjected for 24 h to simvastatin (25 lM)
and/or PX-18 (0.2 mg/ml), and in serum of rats 5 days after
AMI, since theoretically then sPLA2-IIA activity is maxi-
mal, according to human data.(11) Activity was measured
with or without adding of PX-18, according to manufac-
turer’s protocol (Cayman Chemical, Ann Arbor, MI, USA).
In brief 10 ll of cell lysate or serum was added to an assay
mix containing the substrate diheptanoyl phosphatidyl-
choline, and 5,5-dithio-bis-2-nitrobenzoic acid (DTNB).
sPLA2-IIA activity was determined by measuring the
release of free thiols in a microplate fluorescence reader
(TECAN).
Western blot analysis
H9c2 cells were lysed in lysis-buffer containing 0.001%
NP-40, 2.5 mM Tris–HCl, 150 mM NaCl, and 5 mM
EDTA in water. Protein concentration was determined
using the BCA protein assay kit (Pierce, Rockford, IL,
USA). Then reducing sample loading buffer (0.25 M TRIS
pH 6.8, sodium dodecyl sulfate (SDS), glycerol, 2-
mercaptoethanol, bromophenol blue) was added and the
samples were mixed and heated at 95C for 5 min. Proteins
were subjected to SDS–PAGE, and transferred to nitro-
cellulose membranes. Membranes were incubated with
primary antibodies overnight at 4C (mouse-anti-rat
sPLA2-IIA, 1:250, 2B7/2E7, kindly provided by Dr. CG
Schalkwijk, AZM Maastricht, the Netherlands, and b-actin,
1:4,000, BD Biosciences, Franklin Lakes, NJ, USA).
Next, membranes were incubated with rabbit-anti-mouse
antibody horseradish peroxidase conjugated for 1 h at
room temperature (DakoCytomation, 1:1,000). Blots were
visualised by enhanced chemiluminescence (1:40, ECL;
Amersham Bioscience AB, Buckinghamshire, UK), and
quantified using a charge couple device camera (Fuji Science
Imaging Systems) in combination with AIDA Image Analyzer
software (Isotopenmessgera¨te; Staubenhardt, Germany).
Statistical analysis
Statistical analysis was performed using GraphPad Prism 4
software. A t-test was performed for two groups and
ANOVA was used for more groups, if scores were dis-
tributed normally. In case scores were not distributed
normally, a Mann–Whitney test or Kruskall–Wallis test
was used for analysis. A Pearson chi-square test was used
for analysis of discrete values. A P-value smaller than 0.05
was considered to be statistically significant. In the text and
figures values are given as mean ± standard error.
Results
PX-18 reduces infarct size and mortality in a rat model
of AMI
In sham operated rats, superficial wounds showing fibrosis
and granulation tissue formation were induced, but only at
the epicardial site of the heart (Fig. 1c). In contrast, in rats
with AMI areas of fibrosis and/or granulation tissue were
found in all areas of the ventricular wall (Fig. 1d,e).
It has been described recently that PX-18 is a specific
sPLA2-IIA inhibitor.[13, 16] We validated this inhibitory
effect of PX-18 in vivo in the serum of rats 5 days after MI
and found that PX-18 indeed significantly reduced sPLA2
activity, namely a reduction of 25% (not shown). Notably,
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the assay we used could only detect total sPLA2 activity,
not sPLA2-IIA activity specificially.
In rats treated with PX-18 infarct size was significantly
decreased over 70% when compared to vehicle treated rats,
namely from 5.6 ± 2.7% to 1.5 ± 0.5% infarct area/left
ventricle area (P \ 0.05; Fig. 1b). Further, we did not find
significant differences in wall thickness or immunohisto-
logically in scar tissue formation (amount of fibrosis and
granulation tissue) between groups receiving PX-18 or
vehicle. Interestingly, all rats treated with PX-18 (n = 17)
survived after AMI. In contrast, in the vehicle group 3 out
of 13 rats died within 2 days after infarction (2 rats during
the first day and 1 rat during the second day after AMI),
thus during the acute inflammation period (P \ 0.05).
We further analyzed putative depositions of sPLA2-IIA in
the hearts of rats after AMI. We found expression of
sPLA2-IIA on inflammatory cells in the infarcted area
28 days after AMI (Fig. 2b). However, sPLA2-IIA expres-
sion could not be detected on cardiomyocytes 28 days after
AMI (Fig. 2a). In contrast, in rats with AMI of 5 days old,
derived from another study unrelated to PX-18, sPLA2-IIA
was found on jeopardized cardiomyocytes (Fig. 2c), which
confirms the presumption that sPLA2-IIA is mainly found
within the acute inflammation period after AMI [4, 11].
Cardiac output was calculated using parasternal short
axis left ventricular systolic and diastolic diameters as has
been described, and compared to standard values in the
literature of rats of the same weight [17]. In vehicle rats the
cardiac output was reduced to 85% (39.6 ± 7 ml/min) of
the normal value (46.3 ml/min), whereas in PX-18 treated
animals the cardiac output was 97% (45 ± 8 ml/min) of
the normal value (P = 0.27 PX-18 versus vehicle; Fig. 3a).
No differences were found in cardiac output between sham
operated rats and AMI rats (not shown). In addition, in
PX-18 treated rats stroke volume was 15 ± 6% higher
compared to vehicle treated rats (PX-18 0.11 ± 0.02 ml
versus 0.13 ± 0.02 ml in vehicle treated rats; P = 0.10;
Fig. 3b), however, neither of these parameters differed
significantly between the groups.
PX-18 does not affect neutrophilic granulocyte
infiltration at 28 days post AMI, but does increase
macrophage infiltration
To investigate the effect of PX-18 on inflammatory cell
number, to exclude a possible delay of inflammation by
PX-18, we analyzed the presence of neutrophilic granulo-
cytes and macrophages in the infarcted myocardium
Fig. 2 Immunohistochemical staining of sPLA2-IIA expression in
the rat heart after AMI. No sPLA2-IIA expression was found on
cardiomyocytes 28 days after AMI in both the vital (a) en the
infarcted (b) area. sPLA2-IIA expression was found in inflammatory
cells in the infarction area (b, see arrows). c As a positive control, at
5 days post AMI, sPLA2-IIA depositions were found on jeopardized
cardiomyocytes in the infarction area in untreated AMI rats (arrows).
Magnification a, b, c: 2009
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Fig. 3 Effects of PX-18 on heart function. a Relative cardiac output
(CO) was increased from 85 ± 7% to 97 ± 6% of the normal value
(46.3 ml/min) in rats receiving PX-18, compared to vehicle-treated
rats (P = 0.27, one-sided Mann–Whitney test). b Relative stroke
volume compared to vehicle-treated rats (100%) was increased with
15 ± 6% (P = 0.10, one-sided t-test) in the group receiving PX-18
Apoptosis (2009) 14:753–763 757
123
(infarcted area and borderzone) as well as viable myocar-
dium of the left ventricle (Fig. 4).
The total amount of neutrophilic granulocytes in the
non-infarcted areas of the left ventricle of AMI rats was
significantly higher than in the hearts of the sham operated
controls(vehicle 0.8 versus 0.1 granulocytes/mm2 in sham,
P \ 0.05, Fig. 4a). Although we observed a significant
number of neutrophilic granulocytes in the infarct, this
number of neutrophilic granulocytes at 28 days post AMI
is very low when compared to the period short after AMI
(unpublished results).
No differences in total neutrophilic granulocyte amount
were found between the vehicle and PX-18 AMI groups
(Fig. 4b), suggesting that inflammation was not delayed.
Macrophages were predominantly found in infarcted
areas of the heart, with numbers being up to 60 times
higher in infarcted myocardium compared to viable
myocardium Furthermore, in viable myocardium macro-
phages were diffusely solitary present within the tissue,
whereas in the infarcted myocardium the macrophages
were predominantly found in large conglomerates. The
amount of macrophages was significantly increased after
treatment with PX-18 compared to vehicle-treated rats, in
both the infarction areas (P \ 0.05) as well as the viable
myocardium of the left ventricle (P \ 0.01, Fig. 4c,d).
Thus, inhibition of sPLA2-IIA in vivo, using the specific
sPLA2-IIA inhibitor PX-18, resulted in a significant
reduction of sPLA2-IIA activity in rat serum, a significant
reduction of infarct size, a significantly higher survival rate
and a significant increase in the amount macrophages
compared to vehicle treated rats.
To further investigate the type of macrophages found
within the heart, we stained serial slides with a CD68
antibody, which stains all macrophages (Fig. 4e) and an
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Fig. 4 Effects of PX-18 on
neutrophilic granulocyte and
macrophage infiltration.
Amount of neutrophilic
granulocytes (a ? b) and
macrophages (c ? d).
a Amount of neutrophilic
granulocytes in the noninfarcted
areas of the left ventricle.
Significantly more neutrophilic
granulocytes were found in
infarcted animals, compared to
sham operated animals (Kruskal
Wallis). b: Amount of
neutrophilic granulocytes in the
infarcted area of the left
ventricle. No significant
differences were found between
PX-18 treated and untreated
animals. c Amount of
macrophages in the
noninfarcted areas of the left
ventricle. Significantly more
macrophages were found in
PX-18 treated animals,
compared to sham operated and
vehicle treated animals (Kruskal
Wallis). d Amount of
macrophages in the infarcted
area of the left ventricle.
Significantly more macrophages
were found in PX-18 treated
animals, compared to vehicle
treated animals (unpaired t-test).
* P \ 0.05, ** P \ 0.01. e
Immunohistochemical staining
for CD68, staining all types of
macrophages (arrows). f
Immunohistochemical staining
for ED2, staining the late type
of macrophages (arrows).
Magnification e, f: 2009
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ED2 antibody (Fig. 4f), which stains resident/late macro-
phages [14]. The majority of the macrophages in both the
vehicle and the PX-18 group stained positive with this ED2
antibody, suggesting that the macrophages found were late
type macrophages that promote healing (Fig. 4).
PX18 Decreases membrane flip-flop and apoptosis in
rat cardiomyoblasts in vitro independent of sPLA2-IIA
Since RNA expression of sPLA2-IIA has been shown in
cardiomyocytes under conditions of stress,[18, 19] we
investigated the putative effect of PX-18 on rat cardio-
myoblasts in vitro. Previously, we have found that ische-
mia resulted mainly in an increase in annexin V/PI positive
H9C2 cells (late apoptotic/dead cells), whereas the induced
number of single-annexin V positive cells (early apoptotic/
reversibly damaged) was limited [8]. As the HMG-CoA
reductase inhibitor simvastatin has been shown to induce
apoptosis and membrane flip-flop in cardiomyocytes,[15]
we studied the effect of PX-18 on simvastatin induced
(reversible) plasma membrane flip-flop in H9c2 cells and
apoptosis.
Simvastatin (25 lM, 24 h incubation) significantly
increased the percentage of single-annexin V positive cells
to 23 ± 2% compared with 5 ± 1% in control cells
(P \ 0.001; Fig. 5a), and decreased the percentage of
viable cells (P \ 0.01). This effect was completely neu-
tralized by mevalonate (6 ± 0% single annexin V positive
cells), indicating that the effects induced by simvastatin are
indeed the result of its inhibition of HMG-CoA reductase.
zVAD (pan-caspase inhibitor) reduced the percentage of
single-annexin V-positive cells to 16 ± 6%, however this
reduction was not significant Fig. 5b). Furthermore, the
percentages of single-annexin V positive cells after treat-
ment with simvastatin and zVAD were still significantly
higher than in control cells (P \ 0.01), indicating that the
major part of the simvastatin-induced membrane flip-flop
was reversible damaged and not apoptotic.
We next analyzed the effect of PX-18 hereon. We found
that PX-18 did not induce an increase in single annexin V
positivity of control cells (not subjected to simvastatin),
and thus did not have a toxic effect on cells. We further
found that PX-18 significantly reduced the percentage of
simvastatin induced single-annexin V positive cells from
22 ± 8% to 6 ± 4% (control level 7 ± 5%, P \ 0.001;
Fig. 5b).The combination of PX-18 and zVAD did not
further reduce the number of annexin V positive cells,
when compared to PX-18 alone, indicating that PX-18
inhibits both apoptotic and reversibly flip-flopped cells.
The anti-apoptotic effect of PX-18 was further validated
by measuring active caspase 3. Simvastatin indeed signif-
icantly increased active caspase 3 concentration with
300 ± 74% compared to control cells (P \ 0.001). Again
it is shown that mevalonate completely neutralized this
effect of simvastatin, confirming that the effects induced by
simvastatin are the result of its inhibition of HMG-CoA
reductase. Caspase-3 activity induced by simvastatin was
significantly reduced to 33 ± 14% nM above control level
by PX-18 (P \ 0.001; Fig. 5c). The PX-18 treated group
did not differ significantly from the control group, nor from
the positive control zVAD, indicating that PX-18 protected
all apoptotic cells induced by simvastatin. To investigate
whether this effect of PX-18 on simvastatin induced
membrane flip-flop was sPLA2-IIA mediated, sPLA2-IIA
activity was quantified in H9c2 cells and in culture medium
of H9c2 cells. However, no sPLA2-IIA activity was
detected in untreated H9c2 cells, cells subjected to sim-
vastatin, cells subjected to only PX-18, in cells subjected to
PX-18 and simvastatin, nor in the corresponding culture
media (not shown). In line with this, sPLA2-IIA expression
could not be detected in any of the samples using western
blot (Fig. 5d). This therefore suggests that the PX-18
inhibitory effect on simvastatin-induced membrane flip-
flop and apoptosis was independent of sPLA2-IIA activity.
Discussion
In this study, we analyzed the effect of the sPLA2-IIA
inhibitor PX-18 on infarct size and heart function in a rat
AMI-model, and on membrane flip-flop and apoptosis in
cardiomyocytes in vitro. In vivo, treatment with PX-18
significantly reduced sPLA2-IIA activity, infarct size
and mortality, without impairing wound healing. In vitro,
PX-18 treatment significantly reduced membrane flip-flop,
as well as apoptosis in cardiomyocytes, independent of
sPLA2-IIA.
Previously we have shown that sPLA2-IIA deposits in
the heart after AMI in the infarcted areas, where CRP and
complement also bind [4]. In addition, sPLA2-IIA was also
found to bind to reversibly damaged, flip-flopped cardio-
myocytes in the borderzones of infarction, and then
induced cell death [8]. This led to the hypothesis that in the
heart after AMI, sPLA2-IIA inhibition would result in
decreased cardiomyocyte death. We now for the first time
show that a specific inhibitor of sPLA2-IIA indeed
decreased myocardial infarct size in vivo.
Inhibition of this inflammatory response has been shown
to impair wound healing and to induce severe conse-
quences such as wall rupture [20, 21]. Importantly, in our
study, sPLA2-IIA inhibition by PX-18 did not result in
reduced ventricular wall thickness, nor in aneurysmatic
infarcts, indicating that wound healing was not impaired.
This is in agreement with findings that in the absence
of sPLA2-IIA, CRP could still bind to necrotic
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cardiomyocytes, indicating that necrotic tissue can still be
cleared via CRP-complement dependent interactions with
phagocytic cells [2, 8].
In addition, we found that PX-18 treatment did not
significantly affect the amount of neutrophilic granulocytes
in the heart 28 days after MI, suggesting that neutrophilic
granulocyte infiltration was also not delayed. Interestingly,
the amount of macrophages in both the infarcted and non-
infarcted areas of the heart were significantly increased
28 days after AMI in rats treated with PX-18 compared
with vehicle treated rats. It is known that macrophages play
an important role in wound healing after AMI.
Roles for macrophages in wound healing after AMI are
digestion of damaged tissue, promotion of angiogenesis,
production of anti-inflammatory mediators, and regulation
of extracellular matrix metabolism through synthesis of
matrix metalloproteinases and their inhibitors [22, 23].
However several different subtypes of macrophages exist,
that may play a different role during inflammation [24].
Nahrendorf et al. [23] have described different roles for these
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Fig. 5 PX-18 decreases simvastatin induced membrane flip-flop and
caspase-3 activity. The effect of PX-18 on simvastatin induced
membrane flip-flop and apoptosis. a Percentages of single-annexin
V-positive cells. Cells were subjected for 24 h to 25 lmol/l simva-
statin or to simvastatin and 250 lmol/l mevalonate. b Percentages of
single-annexin V-positive cells. Cells were incubated ± simvastatin
(25 lM) ± PX-18 (0.2 mg/ml) for 24 h and/or ± zVAD (25 lM) for
24 h. c Concentrations of active caspase-3 when compared to
control cells. Cells were incubated ± simvastatin (25 lM) ± PX-18
(0.2 mg/ml) for 24 h and/or ± zVAD (25 lM) and/or ± 250 lmol/l;
mevalonate for 24 h. * P \ 0.05, ** P \ 0.01, *** P \ 0.001. d
sPLA2-IIA is not expressed in H9c2 cells.Western blot analysis of
sPLA2-IIA expression in H9c2 cells. Cells were incubated ± simva-
statin (25 lM) ± PX-18 (0.2 mg/ml) for 24 h. I, sPLA2-IIA expres-
sion is only detected in the positive control (serum of rat 5 days after
AMI); II, Loading control b-actin is expressed in all samples; ?,
Positive control, rat serum 5 days after AMI; C, unstimulated H9c2
cells; S, H9c2 cells with simvastatin; P, H9c2 cells with simvastatin
and PX-18
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subtype of macrophages in the early and in the late phase of
infarction. They have suggested that early macrophages
digest damaged tissue, while late macrophages promote
healing. We therefore investigated whether the macrophages
we had found in the heart were of this late cell type, by
staining with an ED2 antibody [14]. Indeed we found that the
majority of macrophages stained positive with this ED2
antibody in the infarcted heart 28 days after AMI, suggesting
that these are the late/healing type of macrophages (Fig. 4f),
indicative for another positive effect of PX-18.
In this study we also found a trend towards increased
cardiac output and stroke volume in the PX-18 treated
group, compared to the vehicle treated group, although this
was not statistically significant. It has been shown that
cardiac output is only significantly decreased in large
infarcts [25]. Further, heart function parameters were
shown to be most improved after treatments of relatively
large infarcts [26, 27]. In our study, the infarcts were non-
aneurysmatic, which could explain its small effect on heart
function after AMI and in turn the small effect of PX-18
treatment on the reduced function. We, however, deliber-
ately induced non-aneurysmatic infarcts in a reperfusion
model since in patients most infarcts are non-aneurysmatic,
because of widespread use of revascularization therapy. In
addition we found in a pilot study that complement inhi-
bition most profoundly reduced infarct size in moderately
sized infarcts, rather than in large aneurysmatic infarcts
(unpublished results).
The effects of the sPLA2-IIA inhibitor PX-18 on cardio-
myocyte flip-flop and apoptosis were further investigated in
vitro. Recently, we and others have shown that membrane
flip-flop can be a reversible phenomenon, also in cardio-
myocytes [7, 28, 29]. We now found that a significant
proportion of the simvastatin induced flip-flopped cardio-
myocytes were reversibly damaged cells, whereas another
proportion was apoptotic and thus irreversibly damaged.
PX18 did prevent apoptosis and membrane flip-flop in
reversibly damaged cardiomyocytes independent of
sPLA2-IIA inhibition, as no activity nor expression of
sPLA2-IIA could be detected in the H9c2 cells under the
investigated conditions. This is in agreement with previous
studies in which mRNA expression, but no protein expres-
sion, of sPLA2-IIA was detected in cardiomyocytes [18, 19].
In this study we thus show several protective roles for
PX-18 after AMI as depicted in Fig. 6. This figure shows
that after AMI reversibly and irreversibly damaged
cardiomyocytes are found. Inflammation targets both these
type of cells. The reversibly damaged cells are removed
CRP
C
of control cells
Plasma membrane Plasma membrane Plasma membrane during
during ischemie post ischemic inflammation.
Reversibly damaged
p
Irreversibly damaged
Extracellular
Intracellular
†
†
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Fig. 6 In vivo mechanisms of cell death during AMI and the effect
of sPLA2-IIA inhibition by PX-18. Ischemia induces reversible and
irreversible membrane flip-flop in cardiomyocytes. During the
subsequent inflammatory reaction, sPLA2-IIA binds to flip-flopped
membranes and induces cell-death. This results in necrosis of both
reversibly as irreversibly damaged cardiomyocytes. PX-18 prevents
cell death of reversibly flip-flopped cardiomyocytes by inhibiting flip-
flop, by inhibiting direct cytotoxic effects of sPLA2-IIA, and also by
inhibiting sPLA2-IIA-facilitated binding of CRP and complement.
Importantly, irreversibly damaged cardiomyocytes can still be cleared
due to binding of CRP independent of sPLA2-IIA. C, complement;
CRP, C-reactive protein; , cell death; \, inhibition; , hydrophobic
phospholipids (phosphatidylcholine) that in normal cells composes
most of the outer leaflet of plasma membranes; d, anionic phospho-
lipids phosphatidylserine (PS) and phosphatidylethanolamine (PE)
that are normally kept within the inner leaflet of the plasma
membrane
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due to binding of sPLA2-IIA, and subsequent binding of
CRP and complement. The irreversibly damaged cells can
also be removed due to direct binding of CRP. PX-18 thus
can exert a protective effect on three different levels: (1)
PX-18 inhibits membrane flip-flop, and thus the pro-
inflammatory state of the plasma membrane. (2) PX-18
inhibits sPLA2-IIA activity, and thus prohibits sPLA2-IIA
mediated cell death of at that moment reversibly damaged
cardiomyocytes. (3) PX-18 inhibits apoptosis.
These results thus show that administration of PX-18 is
an effective therapy in reducing post-infarct inflammatory
damage to the myocardium, without impairing normal
wound healing. These results also show that membrane
flipflop plays a major role in infarct mediated damage of
cardiomyocytes, and that therapy targeting this membrane
flip-flop is promising.
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